ישראל - עברית - Ministry of Health

sanofi israel ltd - insulin glargine - תמיסה להזרקה - insulin glargine 100 u/ml

ישראל - עברית - Ministry of Health

sanofi israel ltd - dupilumab - תמיסה להזרקה - dupilumab 175 mg/ml - dupilumab

ישראל - עברית - Ministry of Health

sanofi - aventis israel ltd - insulin lispro - תמיסה להזרקה - insulin lispro 100 u/ml - insulin lispro

ישראל - עברית - Ministry of Health

sanofi israel ltd - belumosudil as mesylate - טבליות מצופות פילם - belumosudil as mesylate 200 mg - belumosudil

ישראל - עברית - Ministry of Health

sanofi israel ltd - alemtuzumab - תרכיז להכנת תמיסה לאינפוזיה - alemtuzumab 12 mg / 1.2 ml - alemtuzumab

ישראל - עברית - Ministry of Health

sanofi israel ltd - cemiplimab - תרכיז להכנת תמיסה לאינפוזיה - cemiplimab 50 mg / 1 ml - cemiplimab

ישראל - עברית - Ministry of Health

sanofi israel ltd - insulin glargine - תמיסה להזרקה - insulin glargine 300 u/ml - insulin glargine

ישראל - עברית - Ministry of Health

sanofi israel ltd - isatuximab - תרכיז להכנת תמיסה לאינפוזיה - isatuximab 20 mg / 1 ml - isatuximab

ישראל - עברית - Ministry of Health

sanofi - aventis israel ltd - clopidogrel as hydrogen sulfate 300 mg - film coated tablets - clopidogrel - prevention of atherotrobmotic eventsclopidogrel is indicated in :• adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.• adult patients suffering from acute coronary syndrome- non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave myocardial infarction (mi)), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapyprevention of atherotrobmotic and thromboembolic events in atrial fibrillation: in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for the treatment with vitamin k antagonists (vka) anti-thrombin or anti factor xa, and who have a low bleeding risk, clopid

ישראל - עברית - Ministry of Health

sanofi - aventis israel ltd - adenosine - תמיסה להזרקה - adenosine 6 mg / 2 ml - adenosine - adenosine - rapid conversion to a normal sinus rhythm of paroxymal supraventicular tachycardias including those associated with accessory bypass tracts (wolf parkinson-white syndrome).